The British government is under scrutiny for a scandal involving contaminated blood products in the NHS, leading to thousands of deaths.

Internal documents indicate the government opted for cheaper US blood products despite knowing the increased hepatitis risk.

Victims, predominantly haemophiliacs, have not received adequate compensation, with many families still awaiting interim payments.

A public inquiry launched in 2017 has exposed evidence of government negligence and potential commercial motivations behind the scandal.

The inquiry revealed missing documents, a lack of victim notification, and allegations of a widespread criminal cover-up.

While the government has apologized, affected individuals and their families continue to demand recognition and compensation.

Pharmaceutical companies have shown sympathy and cooperated with the ongoing inquiry.

The government admits the need for justice and compensation, yet complexities have delayed resolutions.

The inquiry's final report is due next month, with a parliamentary update on further actions anticipated within 25 sitting days.